|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 39/00 | (2006.01) |
| C07K 16/2818 | (2013.01) | ||
| A61K 39/39 | (2006.01) | ||
| A61K2039/545 | (2013.01) | ||
| A61K 38/20 | (2013.01) | ||
| A61K 39/395 | (2006.01) | ||
| A61K 38/2046 | (2013.01) | ||
| A61K 38/20 | (2006.01) | ||
| A61K 38/2086 | (2013.01) | ||
| C07K 16/28 | (2006.01) | ||
| A61N 5/10 | (2006.01) | ||
| A61K 39/39 | (2013.01) | ||
| A61P 35/04 | (2006.01) | ||
| A61K2039/505 | (2013.01) | ||
| A61P 43/00 | (2006.01) | ||
| A61P 35/00 | (2018.01) | ||
| A61K 35/15 | (2015.01) | ||
| A61P 35/02 | (2018.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61P 37/04 | (2018.01) | ||
| A61P 35/02 | (2006.01) | ||
| A61P 43/00 | (2018.01) | ||
| A61P 37/04 | (2006.01) | ||
| A61K 39/4622 | (2023.05) | ||
| A61K2239/31 | (2023.05) | ||
| A61K 39/4615 | (2023.05) | ||
| A61K2239/47 | (2023.05) | ||
| A61K 39/464499 | (2023.05) | ||
| A61K2239/38 | (2023.05) |
| (11) | Number of the document | 3065772 |
| (13) | Kind of document | T |
| (96) | European patent application number | 14859634.9 |
| Date of filing the European patent application | 2014-11-05 | |
| (97) | Date of publication of the European application | 2016-09-14 |
| (45) | Date of publication and mention of the grant of the patent | 2024-07-24 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2014/064133 |
| Date | 2014-11-05 |
| (87) | Number | WO 2015/069770 |
| Date | 2015-05-14 |
| (30) | Number | Date | Country code |
| 201361900355 P | 2013-11-05 | US | |
| 201361900309 P | 2013-11-05 | US |
| (72) |
BOSCH, Marnix, Leo , US
GANJEI, James, Kelly , US
POWERS, Linda, F. , US
LIAU, Linda, M. , US
PRINS, Robert, M. , US
|
| (73) |
Cognate Bioservices, Inc. ,
7513 Connelley Drive, Hanover, MD 21076,
US
NorthWest Biotherapeutics, Inc. , 4800 Montgomery Lane, Suite 800, Bethesda, MD 20814, US The Regents of the University of California , 1111 Franklin Street, 12th Floor, Oakland, CA 94607, US REVIMMUNE, INC. , 7513 Connelley Drive, Hanover MD 21076, US |
| (54) | COMBINATIONS OF CHECKPOINT INHIBITORS AND THERAPEUTICS TO TREAT CANCER |
| COMBINATIONS OF CHECKPOINT INHIBITORS AND THERAPEUTICS TO TREAT CANCER |